Bloodwise
Posted by

New blood cancer treatments for Scotland

Bloodwise
Posted by
15 Jun 2016

Bloodwise has welcomed two new blood cancer treatments for use in Scotland.

We are delighted that two new blood cancer treatments have been approved for use in the NHS in Scotland by the Scottish Medicines Consortium. The two treatments are:

  • Febuxostat for the prevention and treatment of hyperuricaemia;
  • blinatumomab for the treatment of Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia.

Diana Jupp, Director of Patient Experience at Bloodwise, said:

“It is vital that patients have access to innovative and effective medicines, and it is great news that patients in Scotland will be able to access these two treatments.  We know that there are pressures on the NHS budget, so are very grateful that a Patient Access Scheme was agreed upon between the manufacturer and regulators for blinatumomab to ensure it could be provided for all NHS patients.  Only by industry and regulators working effectively together across the UK’s devolved nations will patients be able to access the treatments they need at a price the NHS can afford.”

Comments

Related blogs